Reminder – Melanoma Consumer Breakfast this Saturday 6th October 2108

Sat 6th October 2018, 8:00-9:30am All members of the melanoma community are invited to attend a Melanoma Consumer Breakfast. The Breakfast is part of the Australasian Melanoma Conference – which also has great consumer forums. The program is on the website. All bookings can be made via the conference website http://australasianmelanoma.org/

Melanoma survivors march to honour lost friends and raise awareness

Melanoma has a reputation for being one of the most curable types of cancers, but that does not mean much to survivors such as Jay Allen and Aaron Kelly.

Free skin checks for South West community

The Bunbury Skin Cancer Clinic is partnering with melanomaWA to provide the community with free skin checks on February 24.

Townsville’s First Ever Twilight Melanoma March

She will next month join Townsville’s first ever twilight Melanoma March in honour of her mother, Gina Sellen, who lost her battle against the deadly cancer in 2016.

Cancer in the News

Feature Articles

Sun protection: New swimwear line has you covered

Source: news.com.au, November 2018 BRISBANE mum Alyshia Morris was shaken to the core when she was diagnosed with two melanomas at the age of 32. She’s turned her negative experience into a positive, coming up with a way to not only stay sun smart herself, but encourage others to do the same. BRISBANE mother Alyshia […]

READ MORE >

Posted in Melanoma News, Patients, Patient Stories

Engineered Anti-MAGE-A T-Cells Show Early Promise

Source: OncLive, November 2018 Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation. The first 6 patients treated with either of 2 doses of engineered T-cells targeting melanoma-associated antigen-A4 (MAGE-A4) had a variety of adverse events (AEs), but treatment-related grade ?3 AEs […]

READ MORE >

Posted in Melanoma News, Health Professionals, Of Interest

Esmo 2018 – Merck & Co fails to Sting

Source:  Evaluate, November 2018 Oncology projects that disrupt the tumour microenvironment are hot property, and – after Aduro’s $225m deal with Novartis and Bristol-Myers Squibb’s $300m takeover of IFM Therapeutics – the Sting pathway is seen as particularly attractive. This is why the first clinical data with Merck & Co’s Sting agonist MK-1454, presented at […]

READ MORE >

Posted in Melanoma News, Health Professionals, Clinical Trials

KEYNOTE022: Triplet therapy for BRAF melanoma

Source: Ecancer, November 2018 Prof Paolo Ascierto speaks with ecancer at ESMO 2018 in Munich about results from a phase 2 randomised study of dabrafenib and trametinib plus PD-L1 checkpoint therapy pembrolizumab for BRAFm advanced melanoma. Prof Ascierto discusses how immuno-oncology is adding to melanoma treatment, with the dabrafenib trametinib combination already found effective in the adjuvant […]

READ MORE >

Posted in Melanoma News, Health Professionals, Clinical Trials